TG THERAPEUTICS, INC. Operating Cash Flow
TG THERAPEUTICS, INC. (TGTX) reported Operating Cash Flow of $21.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- TG THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $39.26M, a 428.01% increase year-over-year.
- TG THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$17.89M.
- TG THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $19.66M.
- TG THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$23.15M.
- TG THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$24.77M.
- TG THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$40.52M.
- TG THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$31.41M.
- TG THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$176.17M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 13 month | Net Cash Provided by (Used in) Operating Activities 15 month | Net Cash Provided by (Used in) Operating Activities 16 month | Net Cash Provided by (Used in) Operating Activities 18 month | Net Cash Provided by (Used in) Operating Activities 19 month | Net Cash Provided by (Used in) Operating Activities 22 month | Net Cash Provided by (Used in) Operating Activities 119 month | Net Cash Provided by (Used in) Operating Activities 122 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $39.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $21.37M 10-Q · filed 2026-08-05 | $41.03M derived: sum of 3 quarters · filed 2026-08-05 | $17.88M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||
| 2026-03-31 | -$17.89M 10-Q · filed 2026-05-06 | $1.77M derived: sum of 2 quarters · filed 2026-05-06 | -$21.39M derived: sum of 3 quarters · filed 2026-05-06 | -$13.95M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||
| 2025-12-31 | $19.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$3.49M derived: sum of 2 quarters · filed 2026-02-27 | $3.94M derived: sum of 3 quarters · filed 2026-08-05 | -$24.77M 10-K · filed 2026-02-27 | ||||||||||
| 2025-09-30 | -$23.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$15.72M derived: sum of 2 quarters · filed 2026-08-05 | -$44.43M 10-Q · filed 2025-11-05 | -$70.07M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||
| 2025-06-30 | $7.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$21.28M 10-Q · filed 2026-08-05 | -$46.92M derived: sum of 3 quarters · filed 2026-08-05 | -$59.13M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||
| 2025-03-31 | -$28.71M 10-Q · filed 2026-05-06 | -$54.36M derived: sum of 2 quarters · filed 2026-05-06 | -$66.56M derived: sum of 3 quarters · filed 2026-05-06 | -$61.02M derived: sum of 4 quarters · filed 2026-05-06 | ||||||||||
| 2024-12-31 | -$25.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$37.85M derived: sum of 2 quarters · filed 2026-02-27 | -$32.31M derived: sum of 3 quarters · filed 2026-02-27 | -$40.52M 10-K · filed 2026-02-27 | ||||||||||
| 2024-09-30 | -$12.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$6.67M derived: sum of 2 quarters · filed 2025-11-05 | -$14.88M 10-Q · filed 2025-11-05 | -$28.09M derived: sum of 4 quarters · filed 2026-02-27 | ||||||||||
| 2024-06-30 | $5.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$2.67M 10-Q · filed 2025-08-08 | -$15.88M derived: sum of 3 quarters · filed 2026-02-27 | $67.82M derived: sum of 4 quarters · filed 2026-02-27 | ||||||||||
| 2024-03-31 | -$8.21M 10-Q · filed 2025-05-09 | -$21.42M derived: sum of 2 quarters · filed 2026-02-27 | $62.29M derived: sum of 3 quarters · filed 2026-02-27 | $20.28M derived: sum of 4 quarters · filed 2026-02-27 | ||||||||||
| 2023-12-31 | -$13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $70.49M derived: sum of 2 quarters · filed 2026-02-27 | $28.49M derived: sum of 3 quarters · filed 2026-02-27 | -$31.41M 10-K · filed 2026-02-27 | ||||||||||
| 2023-09-30 | $83.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $41.70M derived: sum of 2 quarters · filed 2024-11-07 | -$18.20M 10-Q · filed 2024-11-07 | -$42.07M derived: sum of 4 quarters · filed 2025-03-03 | ||||||||||
| 2023-06-30 | -$42.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$101.91M 10-Q · filed 2024-08-09 | -$125.78M derived: sum of 3 quarters · filed 2025-03-03 | -$160.27M derived: sum of 4 quarters · filed 2025-03-03 | ||||||||||
| 2023-03-31 | -$59.90M 10-Q · filed 2024-05-06 | -$83.77M derived: sum of 2 quarters · filed 2025-03-03 | -$118.27M derived: sum of 3 quarters · filed 2025-03-03 | -$167.38M derived: sum of 4 quarters · filed 2025-03-03 | ||||||||||
| 2022-12-31 | -$23.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$58.37M derived: sum of 2 quarters · filed 2025-03-03 | -$107.48M derived: sum of 3 quarters · filed 2025-03-03 | -$176.17M 10-K · filed 2025-03-03 | ||||||||||
| 2022-09-30 | -$34.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$83.61M derived: sum of 2 quarters · filed 2023-11-06 | -$152.30M 10-Q · filed 2023-11-06 | -$239.21M derived: sum of 4 quarters · filed 2024-02-29 | ||||||||||
| 2022-06-30 | -$49.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$117.81M 10-Q · filed 2023-08-04 | -$204.71M derived: sum of 3 quarters · filed 2024-02-29 | -$271.92M derived: sum of 4 quarters · filed 2024-02-29 | ||||||||||
| 2022-03-31 | -$68.69M 10-Q · filed 2023-05-08 | -$155.60M derived: sum of 2 quarters · filed 2024-02-29 | -$222.80M derived: sum of 3 quarters · filed 2024-02-29 | -$282.97M derived: sum of 4 quarters · filed 2024-02-29 | ||||||||||
| 2021-12-31 | -$86.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$154.11M derived: sum of 2 quarters · filed 2024-02-29 | -$214.28M derived: sum of 3 quarters · filed 2024-02-29 | -$295.63M 10-K · filed 2024-02-29 | ||||||||||
| 2021-09-30 | -$67.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$127.37M derived: sum of 2 quarters · filed 2022-11-09 | -$208.72M 10-Q · filed 2022-11-09 | -$260.75M derived: sum of 4 quarters · filed 2023-03-01 | ||||||||||
| 2021-06-30 | -$60.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$141.52M 10-Q · filed 2022-08-09 | -$193.55M derived: sum of 3 quarters · filed 2023-03-01 | -$250.08M derived: sum of 4 quarters · filed 2023-03-01 | ||||||||||
| 2021-03-31 | -$81.36M 10-Q · filed 2022-05-10 | -$133.38M derived: sum of 2 quarters · filed 2023-03-01 | -$189.91M derived: sum of 3 quarters · filed 2023-03-01 | -$233.75M derived: sum of 4 quarters · filed 2023-03-01 | ||||||||||
| 2020-12-31 | -$52.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$108.56M derived: sum of 2 quarters · filed 2023-03-01 | -$152.39M derived: sum of 3 quarters · filed 2023-03-01 | -$214.51M 10-K · filed 2023-03-01 | ||||||||||
| 2020-09-30 | -$56.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$100.37M derived: sum of 2 quarters · filed 2021-11-08 | -$162.48M 10-Q · filed 2021-11-08 | -$192.87M derived: sum of 4 quarters · filed 2022-03-01 | ||||||||||
| 2020-06-30 | -$43.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$105.95M 10-Q · filed 2021-08-06 | -$136.34M derived: sum of 3 quarters · filed 2022-03-01 | -$169.54M derived: sum of 4 quarters · filed 2022-03-01 | ||||||||||
| 2020-03-31 | -$62.12M 10-Q · filed 2021-05-10 | -$92.51M derived: sum of 2 quarters · filed 2022-03-01 | -$125.71M derived: sum of 3 quarters · filed 2022-03-01 | -$161.57M derived: sum of 4 quarters · filed 2022-03-01 | ||||||||||
| 2019-12-31 | -$30.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$63.59M derived: sum of 2 quarters · filed 2022-03-01 | -$99.45M derived: sum of 3 quarters · filed 2022-03-01 | -$132.81M 10-K · filed 2022-03-01 | ||||||||||
| 2019-09-30 | -$33.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$69.06M derived: sum of 2 quarters · filed 2020-11-09 | -$102.41M 10-Q · filed 2020-11-09 | |||||||||||
| 2019-06-30 | -$35.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$69.21M 10-Q · filed 2020-08-10 | ||||||||||||
| 2019-03-31 | -$33.35M 10-Q · filed 2020-05-11 | |||||||||||||
| 2018-12-31 | -$128.93M 10-K · filed 2021-03-01 | |||||||||||||
| 2017-12-31 | -$93.76M 10-K · filed 2020-03-02 | |||||||||||||
| 2013-09-30 | -$1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | -$3.71M derived: sum of 2 quarters · filed 2013-11-14 | -$5.92M 10-Q · filed 2013-11-14 | -$6.75M derived: sum of 4 quarters · filed 2013-11-14 | -$11.19M 10-Q · filed 2013-11-14 | |||||||||
| 2013-06-30 | -$2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$4.76M 10-Q · filed 2013-08-09 | -$5.59M derived: sum of 3 quarters · filed 2013-08-09 | -$8.59M derived: sum of 4 quarters · filed 2013-11-14 | -$10.04M 10-Q · filed 2013-08-09 | |||||||||
| 2013-03-31 | -$2.20M 10-Q · filed 2013-05-14 | -$3.04M derived: sum of 2 quarters · filed 2013-05-14 | -$6.03M derived: sum of 3 quarters · filed 2013-11-14 | -$6.53M derived: sum of 4 quarters · filed 2013-11-14 | -$7.48M 10-Q · filed 2013-05-14 | |||||||||
| 2012-12-31 | -$833.33K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-21 | -$3.83M derived: sum of 2 quarters · filed 2013-11-14 | -$4.33M derived: sum of 3 quarters · filed 2013-11-14 | -$5.19M 10-K · filed 2013-03-21 | -$5.27M 10-K · filed 2013-03-21 | |||||||||
| 2012-09-30 | -$2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | -$3.49M derived: sum of 2 quarters · filed 2013-11-14 | -$4.35M 10-Q · filed 2013-11-14 | -$4.41M derived: sum of 4 quarters · filed 2013-11-14 | -$4.44M 10-Q · filed 2012-11-14 | |||||||||
| 2012-06-30 | -$499.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$1.36M 10-Q · filed 2013-08-09 | -$1.42M derived: sum of 3 quarters · filed 2013-08-09 | -$1.45M derived: sum of 4 quarters · filed 2013-08-09 | -$1.45M 10-Q/A · filed 2012-09-07 | |||||||||
| 2012-03-31 | -$861.63K 10-Q · filed 2013-05-14 | -$918.10K derived: sum of 2 quarters · filed 2013-05-14 | -$948.21K derived: sum of 3 quarters · filed 2013-05-14 | -$948.21K 10-Q · filed 2012-05-14 | ||||||||||
| 2011-12-31 | -$56.46K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-21 | -$86.58K derived: sum of 2 quarters · filed 2013-03-21 | -$86.58K 10-K · filed 2013-03-21 | |||||||||||
| 2011-09-30 | -$30.11K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-14 | -$30.11K 10-Q · filed 2012-11-14 | -$166.39K 10-Q · filed 2011-11-14 | -$41.81M 10-Q · filed 2011-11-14 | ||||||||||
| 2011-06-30 | $0.00 10-Q/A · filed 2012-09-07 | $113.84K 10-Q/A · filed 2011-09-14 | -$41.53M 10-Q/A · filed 2011-09-14 | |||||||||||
| 2010-09-30 | -$412.73K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | -$1.43M 10-Q · filed 2011-11-14 | ||||||||||||
| 2010-06-30 | -$1.02M 10-Q/A · filed 2011-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |